Gamma-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it

Abstract

A γ-Crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.

1 . A γ-Crystalline form of ivabradine hydrochloride of formula (I): 
       
         
           
           
               
               
           
         
       
     
     
         2 . The γ-Crystalline form of ivabradine hydrochloride of  claim 1  having a powder X-ray diffraction diagram exhibiting peaks at 4.2 and 13.4 deg 2 theta. 
     
     
         3 . The γ-Crystalline form of ivabradine hydrochloride of  claim 1  having a powder X-ray diffraction diagram exhibiting peaks at 4.2, 13.4, 21.1, 24.2, 24.5 and 26.4 deg 2 theta. 
     
     
         4 . A pharmaceutical composition comprising as active ingredient the γ-crystalline form of ivabradine hydrochloride of  claim 1 , in combination with one or more pharmaceutically acceptable, inert, non-toxic carriers. 
     
     
         5 . A method for treating or preventing a condition requiring a bradycardic, such method comprising administering to a living animal body, including a human, a therapeutically effective amount of the γ-crystalline form of ivabradine hydrochloride of  claim 1 . 
     
     
         6 . A method for treating or preventing clinical situations of myocardial ischaemia and/or a condition involving rhythm disturbances, such method comprising administering to a living animal body, including a human, a therapeutically effective amount of the γ-crystalline form of ivabradine hydrochloride of  claim 1 . 
     
     
         7 . The method of  claim 6 , wherein the clinical situation of myocardial ischaemia is selected from angina pectoris and myocardial infarct and associated rhythm disturbances. 
     
     
         8 . The method of  claim 6 , wherein the condition involving rhythm disturbances is selected from supra ventricular rhythm disturbances and heart failure.